Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06722157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Study acronym: VERDANT
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Oct 16, 2026 to Oct 28, 2026v24
  2. Eligibility criteria expanded, about 10 wordsv23 See this version in full on ClinicalTrials.gov ↗
  3. Enrollment target: 188 to 202 Study sites: 47 to 46v22 Show 1 more changeShow less
    • Study sites: 47 to 46
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 180 to confirmed 188 · Site details revised at 47 of 47 sitesv21 Show 2 more changesShow less
    • Enrollment target: estimated 180 to confirmed 188
    • Site details revised at 47 of 47 sites
  5. Primary completion date: Dec 16, 2026 to Oct 16, 2026 Completion date: Feb 16, 2027 to Oct 16, 2026 · Site details revised at 1 of 47 sitesv20 Show 2 more changesShow less
    • Completion date: Feb 16, 2027 to Oct 16, 2026
    • Site details revised at 1 of 47 sites
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 3 of 47 sitesv19
  2. Site details revised at 1 of 47 sitesv18
  3. Site details revised at 3 of 47 sitesv17
  4. Start date: May 29, 2024 to Jan 6, 2025v16
  5. Site details revised at 2 of 47 sitesv15
  6. Site details revised at 1 of 47 sitesv14
  7. Study sites: 46 to 47 Start date: Jan 6, 2025 to May 29, 2024v13 Show 1 more changeShow less
    • Start date: Jan 6, 2025 to May 29, 2024
  8. Study sites: 48 to 46v12
  9. Eligibility criteria expanded, about 37 wordsv11 See this version in full on ClinicalTrials.gov ↗
  10. Site details revised at 8 of 48 sitesv10
  11. Study sites: 31 to 48v9
  12. Study sites: 30 to 31v8
  13. Study sites: 29 to 30v7
  14. Study sites: 32 to 29v6
  15. Study sites: 36 to 32v5
  16. Study sites: 39 to 36v4
  17. Study sites: 42 to 39v3
  18. Trial status: Not Yet Recruiting to Recruiting Study sites: 41 to 42 · Start date changed from estimate of Dec 26, 2024 to Jan 6, 2025v2 Show 2 more changesShow less
    • Study sites: 41 to 42
    • Start date changed from estimate of Dec 26, 2024 to Jan 6, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
Trial Details
NCT Number NCT06722157
Lead Sponsor Boehringer Ingelheim
Conditions Macular Degeneration, Age-related, Geographic Atrophy
Enrollment 202 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov